COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
The Food and Drug Administration cautioned health care providers against using compounded remdesivir drug products due to the potential for patient exposure to substandard or adulterated products.
The Food and Drug Administration announced that its Vaccines and Related Biological Products Advisory Committee will convene Feb. 26 to discuss the emergency use authorization application by Johnson & Johnson and Janssen Biotech, Inc. for its investigational single-dose COVID-19 vaccine…
About 12. 9 million people received at least one dose of the Pfizer or Moderna COVID-19 vaccines between Dec. 14 and Jan. 14, the first month of the U.S. COVID-19 vaccination program, the Centers for Disease Control and Prevention reported.
The Centers for Disease Control and Prevention reported 10 cases of anaphylaxis, a life-threatening allergic reaction, among the more than 4 million people who received a first dose of the Moderna COVID-19 vaccine between Dec. 21, 2020, and Jan. 10, 2021.
The Centers for Medicare & Medicaid Services (CMS) today released updated guidance putting in place certain limitations on the hospital survey process, including limiting onsite surveys to immediate jeopardy complaint allegations. The limitations will remain in effect for 30 days with the…
The Food and Drug Administration updated its guidance and webpage on COVID-19 convalescent plasma.
The Centers for Medicare & Medicaid Services Jan. 15 released two planning tools to help states return to regular Medicaid and Children’s Health Insurance Program operations after the COVID-19 public health emergency ends, when many flexibilities and waivers granted to states for the emergency…
President-elect Joe Biden named former Food and Drug Administration commissioner David Kessler, M.D., as Chief Science Officer of COVID Response, a role that will assume the responsibilities of the current head of Operation Warp Speed, the Trump administration effort focused on the development and…
Modeling data suggest that the B.1.1.7 variant of SARS-CoV-2 has the potential to increase the U.S. pandemic trajectory in the coming months, the Centers for Disease Control and Prevention reported.
The AHA Jan. 26 at 11 a.m. ET is hosting a Q&A event covering what front-line health care workers need to know about infection prevention and the environment of care.